Pediatric Epilepsy Trial in Subjects 1-24 Months

PHASE2CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions
Epilepsy
Interventions
DRUG

lamotrigine

Trial Locations (65)

1094

GSK Investigational Site, Budapest

1150

GSK Investigational Site, Lisbon

3050

GSK Investigational Site, Parkville, Melbourne

3526

GSK Investigational Site, Miskolc

4012

GSK Investigational Site, Debrecen

4101

GSK Investigational Site, South Brisbane

6720

GSK Investigational Site, Szeged

8034

GSK Investigational Site, Cherry Hill

13210

GSK Investigational Site, Syracuse

13419

GSK Investigational Site, Tallinn

20010

GSK Investigational Site, Washington D.C.

20133

GSK Investigational Site, Milan

22908

GSK Investigational Site, Charlottesville

23298

GSK Investigational Site, Richmond

23510

GSK Investigational Site, Norfolk

27599

GSK Investigational Site, Chapel Hill

27607

GSK Investigational Site, Raleigh

30342

GSK Investigational Site, Atlanta

30912

GSK Investigational Site, Augusta

32207

GSK Investigational Site, Jacksonville

32308

GSK Investigational Site, Tallahassee

32835

GSK Investigational Site, Orlando

35016

GSK Investigational Site, Las Palmas de Gran Canaria

35128

GSK Investigational Site, Padua

37212

GSK Investigational Site, Nashville

40138

GSK Investigational Site, Bologna

43205

GSK Investigational Site, Columbus

44106

GSK Investigational Site, Cleveland

46100

GSK Investigational Site, Mantova

51014

GSK Investigational Site, Tartu

51092

GSK Investigational Site, Reims

64108

GSK Investigational Site, Kansas City

72202

GSK Investigational Site, Little Rock

75230

GSK Investigational Site, Dallas

76104

GSK Investigational Site, Fort Worth

77030

GSK Investigational Site, Houston

80131

GSK Investigational Site, Napoli

80218

GSK Investigational Site, Denver

85712

GSK Investigational Site, Tucson

90027

GSK Investigational Site, Los Angeles

90095

GSK Investigational Site, Los Angeles

97227

GSK Investigational Site, Portland

97239

GSK Investigational Site, Portland

98125

GSK Investigational Site, Messina

11072020

GSK Investigational Site, Beirut

94305-5235

GSK Investigational Site, Stanford

33155-3009

GSK Investigational Site, Miami

33607-6350

GSK Investigational Site, Tampa

40536-0284

GSK Investigational Site, Lexington

55102-2383

GSK Investigational Site, Saint Paul

44308-1062

GSK Investigational Site, Akron

15213-2583

GSK Investigational Site, Pittsburgh

Unknown

GSK Investigational Site, West Heidleberg, Melbourne

GSK Investigational Site, Perth

GSK Investigational Site, Ankara

LV 1004

GSK Investigational Site, Riga

LT-50009

GSK Investigational Site, Kaunas

9713 GZ

GSK Investigational Site, Groningen

3015 GD

GSK Investigational Site, Rotterdam

3584 EA

GSK Investigational Site, Utrecht

3000-075

GSK Investigational Site, Coimbra

4099-001

GSK Investigational Site, Porto

975 17

GSK Investigational Site, Banská Bystrica

833 40

GSK Investigational Site, Bratislava

080 01

GSK Investigational Site, Prešov

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00043875 - Pediatric Epilepsy Trial in Subjects 1-24 Months | Biotech Hunter | Biotech Hunter